Pharmaceutical Research Profile
Symbicort Turbuhaler 60 MD 320/9 mcg AstraZeneca is a pharmaceutical combination inhaler device containing budesonide (320 micrograms) and formoterol fumarate dihydrate (9 micrograms) per metered dose. This AstraZeneca manufactured product represents a fixed-dose combination of an inhaled corticosteroid and a long-acting beta2-adrenergic agonist, designed for respiratory pharmacology research applications. The Turbuhaler device delivers dry powder formulations through its distinctive breath-actuated mechanism, making it suitable for laboratory investigations into inhalation drug delivery systems and respiratory therapeutics. Research scientists studying pulmonary medicine pathways can examine this established pharmaceutical reference standard from Stroid UK Shop alongside other research compounds.
Investigational Applications
Researchers studying respiratory pharmacology investigate combination therapies that target both inflammatory and bronchodilator pathways simultaneously. The budesonide component functions as a synthetic corticosteroid with glucocorticoid activity, while formoterol acts as a selective beta2-adrenoreceptor agonist with rapid onset and prolonged duration characteristics in preclinical models. Laboratory studies examine how these complementary mechanisms work synergistically in cell culture and tissue models. Scientists investigating pharmaceutical compounds can evaluate the pharmacokinetic and pharmacodynamic properties of this established combination therapy. Research applications include studying inhalation delivery mechanisms, comparing dry powder formulations with other delivery systems, and analysing the molecular interactions between corticosteroid and beta-agonist pathways in respiratory tissue models.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Components | Budesonide 320 mcg + Formoterol 9 mcg |
| Delivery System | Turbuhaler dry powder device |
| Metered Doses | 60 actuations |
| Manufacturer | AstraZeneca |
| Formulation Type | Dry powder for inhalation |
| Storage Requirements | Below 30°C, dry conditions |
This pharmaceutical product undergoes rigorous quality control testing by AstraZeneca to ensure consistent dose delivery and device performance. Researchers can verify batch-specific information through manufacturer documentation. The Turbuhaler mechanism requires sufficient inspiratory flow for optimal powder dispersion, making it valuable for studying patient technique variables in clinical research. Laboratory investigations into drug delivery technologies often compare this established device with newer inhalation systems. Scientists examining selective modulators and bioactive peptides appreciate having access to established pharmaceutical references for comparative pharmacology studies.
Research Compliance
This product is supplied exclusively for legitimate scientific research purposes in accredited laboratory environments. Symbicort Turbuhaler requires proper handling protocols and appropriate research facility storage conditions. Not intended for human consumption or therapeutic use outside of approved clinical research settings.
